The InnFocus Story
InnFocus is an ophthalmology company founded in 2004 with extensive biomaterials experience that develops and provides next generation products for glaucoma surgery. Glaucoma is a disease for which there is no cure, is the second leading cause of blindness in the world and afflicts an estimated 60 million people worldwide.
The Company's scientists and engineers are global leaders in the development of highly biocompatible biomaterials and medical devices. The InnFocus MicroShunt™ (formerly known as the "MIDI Arrow") is the first of what the Company expects to be many medical devices that incorporate these materials in the eye. It was developed in collaboration with the University of Miami, Miller School of Medicine, Bascom Palmer Eye Institute.
The MicroShunt™ is a glaucoma drainage implant consisting of a micro-tube about twice the size of an eyelash. It is made from a proprietary biomaterial that demonstrates insignificant inflammation of encapsulation in the eye. It is implanted with the inflow end in the anterior chamber at the angle and the outflow end under the conjunctiva and Tenon's capsule. The mechanism of action for subconjunctival drainage for the MicroShunt™ has been accepted as the gold stand for several decades.
In studies outside the United States, InnFocus has seen sustained Intra Ocular Pressure (IOP) reductions of approximately 50% from baseline with the vast majority of patients maintaining IOP in the mid to low teens for well over two years. Reduced IOP is believed to be required to stop the progression of glaucoma.
MicroShunt acquired CE Mark approval from the National Ministries of Health in 2012 which is mandatory for marketing and selling products in the European markets. The Company has initiated Phase 1 trials via IDE clearance by the U.S. Food and Drug Administration at ten (10) centers in the U.S.
The Company raised $13.4 million in a Series B financing led by the Hoya Group. Hoya is a world leader in ophthalmology. The funds will be used to complete the Phase 1 clinical trials, expand clinical studies in Europe and to invest in the Company's expected growth.